Discovery atClonalStem
Internal research across vascular biology, organoids, and vasculogenesis — translating the unique biology of ECFCs into a pipeline of new therapeutic directions.
Vascular biology as a therapeutic frontier
We build our research around a rare vascular progenitor with an unusual capacity: the ability to assemble new vessel networks from single cells. That biology points toward a broad set of therapeutic opportunities — regenerating vessels in ischemic disease, controlling unwanted vessel growth in cancer and retinal disease, and building more physiologic vascular models in vitro.
Our work starts from a proprietary, clonal, low-passage ECFC bank and uses it as a substrate for discovery across vascular stem cell pharmacology, phenotypic screening, and engineered tissue systems.
What we are exploring
Three overlapping directions built on a single cell source and a common question: how do you pharmacologically control the formation of new blood vessels?
Vascular stem cell pharmacology
Discovering small molecules that mobilize or expand the vascular stem cell population, with the goal of unlocking a regenerative reservoir that has no precedent in clinical pharmacology.
Pro- and anti-vasculogenic screens
Phenotypic screens that identify drugs capable of growing new vessel networks or shutting them down — for ischemia, regenerative medicine, oncology, and ocular vascular disease.
Vascularized organoids
Building perfusable, human vascular beds into organoids and tissue models to improve translational relevance and create better systems for screening, target validation, and mechanism studies.
Vasculogenesis vs. angiogenesis. We focus on the formation of new vessels from progenitor cells — a process distinct from the sprouting of existing vessels and one that may be uniquely relevant when conventional angiogenic approaches fall short in severely ischemic tissue.
From a single cell source to multiple therapeutic directions
Every program is anchored to the same clonal, low-passage CB-ECFC source. This lets us move from cellular mechanism to phenotypic hit, and from hit to counter-screen, without losing the biology that makes the starting population relevant. We run this work internally, with CRO partners, and through collaboration programs that give us access to automated labs and high-density screening infrastructure.
Who we are
Serial founders and translational experts bridging vascular biology, advanced science, and scalable therapeutic development.
Serial entrepreneur translating breakthrough science into clinical-stage cell therapies. Over the last decade he has advanced multiple cellular medicine ventures, several now in clinical development. Committed to disease-modifying and curative medicines for serious conditions.
Translational scientist and biotech entrepreneur with a scientific background spanning small-molecule drug screening to IND-enabling cell and gene therapy, including a successful FDA pre-IND. He also brings expertise in venture creation, commercialization, operations, and investments. Committed to translating breakthrough biology into scalable therapies that improve patient quality of life.
Work with us
We collaborate with pharma, biotech, and academic groups that can benefit from a controlled, clonal vascular cell source and a phenotypic screening platform built around vasculogenesis.
We are open to co-development of therapeutic programs, supply agreements for our low-passage CB-ECFCs, and custom cell line generation for specific disease models or screening needs.